Use of Immune Checkpoint Inhibitors in Solid-Organ Transplant Patients: An Orphan Issue

Area of Science:

• Immunology
• Oncology
• Transplant Medicine

Background:

• Immune checkpoints (e.g., PD-1/PD-L1, CTLA-4) regulate T-cell responses to prevent autoimmunity.
• Cancer cells exploit immune checkpoints to evade immune surveillance.
• Transplant recipients require lifelong immunosuppression to prevent organ rejection.

Purpose of the Study:

• To review the use of immune checkpoint inhibitors (ICIs) in cancer patients who have undergone solid-organ transplantation.
• To analyze the associated risks of organ rejection and other complications.
• To discuss clinical outcomes and future research directions.

Main Methods:

• Literature review of studies on ICI use in transplant recipients with cancer.
• Analysis of clinical cases detailing treatment efficacy and adverse events.
• Examination of the impact of ICIs on graft survival and rejection.

Main Results:

• ICI therapy can be effective in treating cancer in transplant patients.
• A significant risk of acute and chronic organ rejection exists with ICI use.
• Successful management strategies and case reports of both complications and positive outcomes were identified.

Conclusions:

• Balancing cancer treatment with the risk of organ rejection is critical in transplant patients receiving ICIs.
• Careful patient selection, monitoring, and management are essential.
• Further research is needed to optimize ICI therapy in this vulnerable population.